On May 1, local time, the FDA approved Gilead Sciences’ emergency use of the antiviral drug Redsywe, which became the first new drug approved in the United States to target new coronary diseases. But experts still question the effectiveness of the drug’s treatment for new coronary pneumonia, according to data from the Redsey weywe clinical trial, which has been officially published and partially published.
First Financial Reporter recently interviewed Professor Hu Bijie, a member of the Shanghai Medical Treatment Expert Group and director of the Infectious Diseases Department of Zhongshan Hospital affiliated with Fudan University. As an advocate of hydroxychloroquine treatment of the new crown, Hu Bijie believes that hydroxychloroquine is no worse in anti-viral efficacy than redsivir.
In response to the results of Redsey’s treatment of new coronary disease, Hu Bijie recently publicly commented that the best results of two clinical studies in the United States have not met the desired target, and china’s clinical research has concluded that the drug can not reduce the mortality rate of serious patients.
Hu Bijie told the first financial reporter: “Shanghai was the earliest used in clinical hydroxychloroquine, if used alone early, that is, not combined with azithromycin, non-large dose is 400 mg per day, in reducing the death rate of new coronary disease, the effect is not to lose ridsibei.” “
Chloroquine has been in use since the 1940s. Previous papers have demonstrated the potential efficacy of chloroquine for neophed pneumonia. On February 19 this year, Chinese researchers published the results of clinical studies on the treatment of neoprene pneumonia in the online journal Bioscience Trends.
The advantage of using chloroquine treatment is that safety is guaranteed and side effects are relatively small in the case of control of dosage until no specific drugs are available for new coronary pneumonia- The use of hydroxychloroquine and chloroquine phosphate is clinically respected in order to reduce the side effects of chloroquine treatment.
Previously, Zhong Nanshan academician and Shanghai Fudan University affiliated Huashan Hospital infection director Zhang Wenhong has said that from a clinical point of view, hydroxychloroquine has a certain effect, but due to the insufficient sample size, the effect is not enough to draw conclusions.
“Azithromycin’s combination of hydroxychloroquine can be seen as accelerating the virus’s transition,” Zhong Nanshan said at a live television broadcast on April 16. But because the sample is small, it can’t prove that the drug is very, very effective, and we need larger, larger sample size clinical trials. “
Shanghai was the first in the world to use hydroxychloroquine to treat the new coronavirus. Hu Bijie told the first financial reporter: “As far as I have clinically used the feeling is very good, China should study and summarize hydroxychloroquine.” He also said papers on the findings would be published soon.
Since chloroquine and hydroxychloroquine are an old drug that has been used by humans for nearly a century, the price cost is much lower than that of the unapproved drug Ridsywe, which, once proven to be effective, is optimal in terms of the availability and economic utility of the drug.
Professor Yan Xuebing, director of the Infectious Diseases Department at Xuzhou Medical University Hospital, told first financial reporters: “If the drug has antiviral effects, then the concentration of lung drugs with chloroquine or hydroxychloroquine in combination with azithromycin is certainly better than Redcivir.” “
Dr. Shen Hanmin, a professor at the University of Macau and an expert in cell biology, told First Financial That the two drugs, chloroquine and Redsiewe, have different mechanisms to fight the new coronavirus. “Redcivir is a drug specifically designed for RNA viruses, so it should be more effective in terms of mechanism. Dr. Shen told First Financial, “But from the results of clinical trial data, Ridsyway is not as good as expected.” “
Hospitals around the world are currently using chloroquine and hydroxychloroquine to treat new crown patients. Although the FDA announced on its official website that hydroxychloroquine has not shown its effectiveness in treating new coronary pneumonia, the FDA still authorizes hospitals to use hydroxychloroquine in emergencies.
However, recent studies have shown that the use of hydroxychloroquine can lead to a risk of arrhythmia, and further large-scale clinical trials are still under way.
On April 21, the FDA approved pharmaceutical giant Novartis for phase III clinical trials of hydroxychloroquine for the treatment of new coronary pneumonia. The study, which will be conducted in more than a dozen U.S. laboratories, will recruit 440 patients in clinical trials that follow strict design criteria for randomized, double-blind, placebo-controlled trials.
“We recognize the importance of answering the scientific question of whether hydroxychloroquine is beneficial to new corona patients,” said John Tsai, Novartis’ global head of drug development and chief medical officer. Novartis has committed to providing 130 million tablets of hydroxychloroquine worldwide to support clinical research on the drug.